News stories about Cellectis (NASDAQ:CLLS) have been trending somewhat positive on Monday, according to Accern Sentiment. Accern identifies negative and positive news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Cellectis earned a news impact score of 0.10 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 45.7383297985467 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Here are some of the media headlines that may have effected Accern Sentiment Analysis’s rankings:
Shares of Cellectis stock opened at $30.65 on Monday. Cellectis has a 1-year low of $21.25 and a 1-year high of $38.85. The company has a market cap of $1,275.21, a PE ratio of -11.03 and a beta of 1.85.
Cellectis (NASDAQ:CLLS) last issued its quarterly earnings results on Monday, March 12th. The biotechnology company reported ($0.76) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.64) by ($0.12). Cellectis had a negative return on equity of 35.63% and a negative net margin of 298.01%. The firm had revenue of $6.91 million for the quarter, compared to the consensus estimate of $10.10 million. research analysts forecast that Cellectis will post -2.62 earnings per share for the current year.
A number of research firms have issued reports on CLLS. BidaskClub raised shares of Cellectis from a “buy” rating to a “strong-buy” rating in a report on Saturday, February 17th. ValuEngine raised shares of Cellectis from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. Zacks Investment Research downgraded shares of Cellectis from a “hold” rating to a “sell” rating in a report on Wednesday, February 14th. Guggenheim initiated coverage on shares of Cellectis in a report on Friday, March 16th. They issued a “neutral” rating for the company. Finally, Nomura upped their price target on shares of Cellectis to $73.00 and gave the stock a “buy” rating in a report on Wednesday, March 14th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and five have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $42.67.
COPYRIGHT VIOLATION WARNING: This article was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/04/16/cellectis-clls-earns-coverage-optimism-score-of-0-10.html.
Cellectis Company Profile
Cellectis SA, a clinical stage biotechnological company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL).
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.